Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 4/20 | 0.56 |
| ▸ | IGF1R | P08069 | 16/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.53 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.53 |
| ▸ | INSR | P06213 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13629012 | 0.85 | TNK2 (0.52) | TNK2 | |
| SCHEMBL8402327 | 0.83 | FGFR2 (0.52) | TNK2IGF1R | |
| SCHEMBL8400017 | 0.83 | TNK2 (0.53) | TNK2IGF1RCYP3A4 | |
| SCHEMBL10242615 | 0.81 | TNK2 (0.52) | TNK2 | |
| SCHEMBL10242104 | 0.80 | TNK2 (0.42) | TNK2 | |
| SCHEMBL12648255 | 0.80 | TNK2 (0.54) | TNK2IGF1RINSR | |
| SCHEMBL10241497 | 0.80 | RAF1 (0.47) | TNK2IGF1RINSR | |
| SCHEMBL10240981 | 0.79 | RAF1 (0.59) | TNK2IGF1R | |
| SCHEMBL13629011 | 0.78 | TNK2 (0.55) | TNK2IGF1RINSR | |
| SCHEMBL8399399 | 0.78 | RAF1 (0.45) | TNK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | TNK2 669/4885IGF1R 1033/4885CYP3A4 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.